RWE and the Quiet Rewiring of China’s Reimbursement System
Access360 Video Briefing
Over the past year, China’s healthcare security authorities have released a sequence of policy measures that, taken together, signal the early formation of a real-world evidence–enabled governance infrastructure for evaluating and managing the value of both emerging and established medical technologies.
Behind a set of technical documents lies a broader question: how will real-world evidence reshape the governance of pricing, reimbursement, and coverage for medical technologies in China?
This briefing examines the regulatory signals emerging across these policy developments and analyzes how real-world evidence is beginning to reconfigure pricing governance, reimbursement decision-making, and clinical adoption—and what emerging opportunities, risks, and strategic options life sciences manufacturers should consider as the system evolves.
Sections in the briefing
1. Real-World Evidence at the Center of China’s Evolving Reimbursement Architecture
How real-world evidence is beginning to underpin an evolving reimbursement architecture designed to address uncertainty around both emerging and established health technologies.
2. Five Policies Shaping China’s Emerging Real-World Evidence Framework (2025–2026)
An examination of how recent policy milestones are embedding real-world evidence into the governance of medical technology pricing, reimbursement, and clinical adoption.
3. Deep Dive: Policy 4 — RWE Comprehensive Value Assessment Guidelines
How the new guideline begins building the institutional infrastructure for strategic purchasing of medicines, value-based procurement, and the operationalization of China’s multi-layer coverage framework—while introducing mechanisms that may reshape manufacturers’ pricing incentives and the evidentiary environment in which product value is established.
4. Deep Dive: Policy 5 – Reference Drug Pre-Communication Mechanism
How the introduction of a comparator consultation mechanism institutionalizes a structured dialogue between regulators and industry prior to reimbursement evaluation.
How early reference drug alignment may reshape manufacturers’ evidence generation, pricing expectations, and access strategies across the product lifecycle.
5. Strategic Implications for Manufacturers’ Access Strategies Across Five Policies
A synthesis of the key regulatory signals emerging across the five policies, examining the opportunities, risks, and strategic questions they raise for manufacturers planning market access in China.
This briefing is designed for life sciences executives and market access leaders seeking to understand how recent policy developments may reshape the medicine access environment in China.
NRDL+ Masterclass — April Cohort
For readers interested in exploring the broader strategic context behind the developments discussed in this briefing, I will also be hosting a small cohort NRDL+ Masterclass in April titled Navigating China’s Market Access Landscape: Strategic Decision-Making in a Multi-Layer Coverage Environment.
While this video examines how real-world evidence is beginning to reshape elements of China’s reimbursement governance, the Masterclass steps back to examine the broader structure of China’s evolving multi-layer coverage framework and the strategic decision points it creates for manufacturers.
Through a structured three-session cohort format—including a high-density executive briefing, guided reflection using curated Access360 intelligence, and a case-anchored strategic integration discussion—the program helps participants connect policy signals to real-world strategic trade-offs, decision inflection points, and implementation risks embedded within China’s access environment.
For those interested in engaging more deeply with the strategic questions shaping China’s access landscape, more details about the April Masterclass can be found here.
Access360 individual members receive a 20% enrollment benefit for the Masterclass.